{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:10:22Z","timestamp":1792411822887,"version":"4.4.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.vaccine.2018.10.082","type":"journal-article","created":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T09:18:52Z","timestamp":1542187132000},"page":"3754-3760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Monocyte-activation test to reliably measure the pyrogenic content of a vaccine: An in vitro pyrogen test to overcome in vivo limitations"],"prefix":"10.1016","volume":"37","author":[{"given":"Sara","family":"Valentini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Baffetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6675-4540","authenticated-orcid":false,"given":"Sara","family":"Franceschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Paludi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Brandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Gherardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Serruto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Capecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.10.082_b0005","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/am.12.6.483-486.1964","article-title":"Studies on bacterial pyrogenicity. 3. Specificity of the United States pharmacopeia rabbit pyrogen test","volume":"12","author":"Martin","year":"1964","journal-title":"Appl Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2018.10.082_b0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0264-410X(92)90001-Z","article-title":"Potency testing of acellular pertussis vaccines","volume":"10","author":"Robinson","year":"1992","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2018.10.082_b0015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.biologicals.2010.12.001","article-title":"The consistency approach for quality control of vaccines - A strategy to improve quality control and implement 3Rs","volume":"39","author":"De Mattia","year":"2011","journal-title":"Biologicals"},{"issue":"2","key":"10.1016\/j.vaccine.2018.10.082_b0020","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/026119290102900203","article-title":"ECVAM workshop on novel pyrogen tests based on the human fever reaction","volume":"29","author":"Hartung","year":"2001","journal-title":"Altern Lab Anim"},{"issue":"Suppl.","key":"10.1016\/j.vaccine.2018.10.082_b0025","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1093\/ilar.43.Suppl_1.S43","article-title":"Refinement reduction and replacement of animal use for regulatory testing: current best scientific practices for the evaluation of safety and potency of biologicals","volume":"43","author":"Hendriksen","year":"2002","journal-title":"ILAR J"},{"key":"10.1016\/j.vaccine.2018.10.082_b0030","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.provac.2011.10.024","article-title":"Application of the consistency approach to reduce animal use in vaccine potency testing","volume":"5","author":"Kulpa-Eddy","year":"2011","journal-title":"Proc Vaccinol"},{"key":"10.1016\/j.vaccine.2018.10.082_b0035","unstructured":"Russell WMS and Burch RL. The principles of humane experimental technique. Methuen, London; 1959 (Reprinted by UFAW, 1992)."},{"issue":"5459","key":"10.1016\/j.vaccine.2018.10.082_b0040","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","article-title":"Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing","volume":"287","author":"Pizza","year":"2000","journal-title":"Science"},{"issue":"7240","key":"10.1016\/j.vaccine.2018.10.082_b0045","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nature07769","article-title":"Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates","volume":"458","author":"Schneider","year":"2009","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.vaccine.2018.10.082_b0050","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4049\/jimmunol.177.1.501","article-title":"The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance","volume":"177","author":"Madico","year":"2006","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2018.10.082_b0055","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2958.2004.04423.x","article-title":"Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells","volume":"55","author":"Capecchi","year":"2005","journal-title":"Mol Microbiol"},{"issue":"8","key":"10.1016\/j.vaccine.2018.10.082_b0060","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1073\/pnas.0915162107","article-title":"Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans","volume":"107","author":"Serruto","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"10.1016\/j.vaccine.2018.10.082_b0065","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: A randomized comparative trial","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"10061","key":"10.1016\/j.vaccine.2018.10.082_b0070","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/S0140-6736(16)31921-3","article-title":"Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: A national observational cohort study","volume":"388","author":"Parikh","year":"2016","journal-title":"Lancet"},{"issue":"121","key":"10.1016\/j.vaccine.2018.10.082_b0075","first-page":"1","article-title":"Bacterial outer membrane vesicles and vaccine applications","volume":"5","author":"Acevedo","year":"2014","journal-title":"Front Immunol"},{"issue":"29","key":"10.1016\/j.vaccine.2018.10.082_b0080","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2018.10.082_b0085","doi-asserted-by":"crossref","first-page":"47","DOI":"10.14573\/altex.1509291","article-title":"Limitations of the rabbit pyrogen test for assessing meningococcal OMV based vaccines","volume":"33","author":"Vipond","year":"2016","journal-title":"ALTEX"},{"issue":"3","key":"10.1016\/j.vaccine.2018.10.082_b0090","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1017\/S0022172400005052","article-title":"Microorganisms and their relation to fever: preliminary communication","volume":"12","author":"Hort","year":"1912","journal-title":"J Hyg (Lond)"},{"issue":"4","key":"10.1016\/j.vaccine.2018.10.082_b0095","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.3181\/00379727-131-34059","article-title":"Comparative pyrogenic reactivity of rabbit and man to bacterial endotoxin","volume":"131","author":"Greisman","year":"1969","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.vaccine.2018.10.082_b0100","series-title":"Endotoxins - pyrogens, LAL testing and depyrogenation","first-page":"261","article-title":"The pyrogen test","author":"Roberts","year":"2007"},{"key":"10.1016\/j.vaccine.2018.10.082_b0105","first-page":"325","article-title":"A bacterial disease of Limulus polyphemus","volume":"98","author":"Bang","year":"1956","journal-title":"Bull Johns Hopkins Hosp"},{"key":"10.1016\/j.vaccine.2018.10.082_b0110","series-title":"Endotoxins - pyrogens, LAL testing and depyrogenation","first-page":"27","article-title":"Endotoxin relevance and control overview","author":"Williams","year":"2007"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2018.10.082_b0115","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jim.2005.01.010","article-title":"International validation of novel pyrogen tests based on human monocytoid cells","volume":"298","author":"Hoffmann","year":"2005","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2018.10.082_b0120","unstructured":"European Directorate for the Quality of Medicines. Monocyte activation test, Chapter 2.6.30. European Pharmacopoeia 9th ed., Version 9.2; 2017."},{"key":"10.1016\/j.vaccine.2018.10.082_b0125","unstructured":"United States Pharmacopeial Convention. Pyrogen Test, USP <151>. United States Pharmacopeia (USP) 39-NF34; 2016."},{"issue":"2","key":"10.1016\/j.vaccine.2018.10.082_b0130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14573\/altex.1503241","article-title":"The human whole blood pyrogen test - lessons learned in twenty years","volume":"32","author":"Hartung","year":"2015","journal-title":"ALTEX"},{"issue":"3","key":"10.1016\/j.vaccine.2018.10.082_b0135","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/026119291604400305","article-title":"More than 70 years of pyrogen detection: current state and future perspectives","volume":"44","author":"Fennrich","year":"2016","journal-title":"Altern Lab Anim"},{"key":"10.1016\/j.vaccine.2018.10.082_b0140","article-title":"Replacement of the rabbit pyrogen test with the monocyte activation test for the control\/safety testing of an OMV-based Meningococcal B vaccine","author":"Vipond","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.082_b0145","first-page":"73","article-title":"Collaborative study for the establishment of the WHO 3(rd) international standard for endotoxin, the Ph. Eur. endotoxin biological reference preparation batch 5 and the USP reference standard for endotoxin lot H0K354","volume":"2015","author":"Findlay","year":"2015","journal-title":"Pharmeur Bio Sci Notes"},{"key":"10.1016\/j.vaccine.2018.10.082_b0150","first-page":"17","article-title":"Proceedings of the European Workshop on detection and quantification of pyrogen","volume":"1","author":"Poole","year":"1989","journal-title":"Pharmeuropa special"},{"issue":"6","key":"10.1016\/j.vaccine.2018.10.082_b0155","first-page":"362","article-title":"Pharmaceutical approval update","volume":"40","author":"Gohil","year":"2015","journal-title":"Pharm Therapeut PT"},{"key":"10.1016\/j.vaccine.2018.10.082_b0160","unstructured":"TRUMENBA\u00ae (Meningococcal Group B Vaccine) Prescribing Information. Philadelphia, PA: Pfizer, Inc; 2015."},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2018.10.082_b0165","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.vaccine.2003.06.001","article-title":"Post-marketing evaluation of the short term safety of COMVAX","volume":"22","author":"Davis","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.082_b0170","first-page":"131","article-title":"Detection of endotoxins and other pyrogens using human whole blood","volume":"101","author":"Fennrich","year":"1999","journal-title":"Dev Biol Stand"},{"issue":"5","key":"10.1016\/j.vaccine.2018.10.082_b0175","first-page":"238","article-title":"\u2018Monocyte test\u2019 for pyrogen","volume":"1","author":"Poole","year":"1989","journal-title":"Pharmeuropa"},{"issue":"8","key":"10.1016\/j.vaccine.2018.10.082_b0180","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.2042-7158.1991.tb03540.x","article-title":"Assay of pyrogens by interleukin-6 release from monocytic cell lines","volume":"43","author":"Taktak","year":"1991","journal-title":"J Pharm Pharmacol"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2018.10.082_b0185","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jim.2004.03.002","article-title":"Monocyte activation test for pro-inflammatory and pyrogenic contaminants of parenteral drugs: test design and data analysis","volume":"288","author":"Gaines Das","year":"2004","journal-title":"J Immunol Methods"},{"issue":"11","key":"10.1016\/j.vaccine.2018.10.082_b0190","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1002\/pmic.200500821","article-title":"Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98\/254","volume":"6","author":"Vipond","year":"2006","journal-title":"Proteomics"},{"issue":"27","key":"10.1016\/j.vaccine.2018.10.082_b0195","doi-asserted-by":"crossref","first-page":"9577","DOI":"10.1073\/pnas.0502272102","article-title":"The evolution of vertebrate Toll-like receptors","volume":"102","author":"Roach","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.vaccine.2018.10.082_b0200","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/oxfordjournals.jbchem.a135583","article-title":"Structure-activity relationship of Lipid A: comparison of biological activities of national and synthetic Lipid A's with different fatty acid compositions","volume":"99","author":"Kanegasaki","year":"1986","journal-title":"J Biochem"},{"issue":"6","key":"10.1016\/j.vaccine.2018.10.082_b0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.0020067","article-title":"Shield as signal: Lipopolysaccharides and the evolution of immunity to Gram-negative bacteria","volume":"2","author":"Munford","year":"2006","journal-title":"PLoS Pathog"},{"issue":"29","key":"10.1016\/j.vaccine.2018.10.082_b0210","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1016\/j.vaccine.2018.05.073","article-title":"Collaborative Study Group. Evaluation of the monocyte activation test for the safety testing of meningococcal B vaccine Bexsero: A collaborative study","volume":"37","author":"Findlay","year":"2019","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2018.10.082_b0215","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/09680519060120030401","article-title":"Endotoxin evaluation of eleven lipopolysaccharides by whole blood assay does not always correlate with Limulus amebocyte lysate assay","volume":"12","author":"Dehus","year":"2006","journal-title":"J Endotoxin Res"},{"issue":"21","key":"10.1016\/j.vaccine.2018.10.082_b0220","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2174\/092986709788682001","article-title":"The expression of endotoxic activity in the Limulus test as compared to cytokine production in immune cells","volume":"16","author":"Brandenburg","year":"2009","journal-title":"Curr Med Chem"},{"issue":"1","key":"10.1016\/j.vaccine.2018.10.082_b0225","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1753425909106447","article-title":"Structural prerequisites for endotoxic activity in the Limulus test as compared to cytokine production in mononuclear cells","volume":"16","author":"Gutsmann","year":"2010","journal-title":"Innate Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2018.10.082_b0230","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1208\/s12248-016-9979-x","article-title":"The dual role of lipids of the lipoproteins in Trumenba, a self-adjuvanting vaccine against meningococcal meningitis B disease","volume":"18","author":"Luo","year":"2016","journal-title":"AAPS J"},{"key":"10.1016\/j.vaccine.2018.10.082_b0235","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.4049\/jimmunol.168.4.1533","article-title":"Cutting edge: Immune stimulation by Neisserial porins is Toll-like receptor 2 and MyD88 dependent","volume":"168","author":"Massari","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.10.082_b0240","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-3-319-33826-2_3","article-title":"Regulatory acceptance of alternative methods in the development and approval of pharmaceuticals","volume":"856","author":"Beken","year":"2016","journal-title":"Adv Exp Med Biol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18314695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18314695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:32:40Z","timestamp":1759401160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18314695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":48,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0264410X18314695"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.10.082","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monocyte-activation test to reliably measure the pyrogenic content of a vaccine: An in vitro pyrogen test to overcome in vivo limitations","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.10.082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}